TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07527650: Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

Sponsor: Hanmi Pharmaceutical Company Limited · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 180 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,357,200

Rescue Site Savings

+$1,560,400

Unlock Full NCT07527650 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07527650 Rescue Dossier →